Trubion Pharmaceuticals trubion.com


Public list: Pharma Startups (4740) Cancer Therapeutics (1146)

Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The Company's product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.

Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The Company's product candidates are novel proteins known as single-chain polypeptides and are designed using our...Show all

Company (Acquired)

Phone: 206-838-0500

Fax:

2401 4th Avenue
Suite 1050
Seattle, 98121
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Trubion Pharmaceuticals $97.8M Aug 13, 2010
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Trubion Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 7 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Solasia Pharma

Tokyo, Japan
IPO / Went publicSolasia Pharma, formerly known as JapanBridge, expedites patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia has Asian rights to Sancuso (extended release granisetron transdermal patch) from ProStrakan Group plc and an exclusive license to ZIOPHARM's SP-02 / darinaparsin, in major Asian countries. Solasia is currently conducting a Phase 1 study of darinaparsin in PTCL in Japan and ...Show allLogin to see details

Ribozyme Pharmaceuticals

Folsom, California, United States
Alive / ActiveRibozyme Pharmaceuticals offers RNA-based pharmaceuticals for human diseaseLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Materials and methods for improved immunoglycoproteins Apr 11, 2008 Dec 07, 2010 Patent
Binding constructs and methods for use thereof Jul 26, 2003 Nov 09, 2010 Patent
Binding constructs and methods for use thereof Dec 24, 2003 Jul 13, 2010 Patent
Binding domain-immunoglobulin fusion proteins Jul 25, 2002 Jul 13, 2010 Patent